14-3-3σ Contributes to Radioresistance by Regulating DNA Repair and Cell Cycle via PARP1 and CHK2 by Chen, Yifan et al.
14-3-3σ Contributes to Radioresistance by Regulating DNA Repair and Cell Cycle via 
PARP1 and CHK2 
Yifan Chen1,2,3, Zhaomin Li1, Zizheng Dong1, Jenny Beebe1, Ke Yang2, Liwu Fu2,3,*, Jian-
Ting Zhang1,* 
1Departments of Pharmacology and Toxicology and IU Simon Cancer Center, Indiana 
University School of Medicine, Indiana University-Purdue University Indianapolis, 
Indianapolis, IN 46202, USA 
2Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in 
South China, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China 
3Guangdong Esophageal Cancer Institute, Guangzhou, 510060, China 
Running Title：14-3-3σ Enhances DNA DSB Repair Activity 
*Corresponding authors: Jian-Ting Zhang, IU Simon Cancer Center, Indiana University
School of Medicine, 980 W. Walnut St., Indianapolis, IN 46202; Tel. (317) 278-4503; E-mail 
address:  jianzhan@iu.edu and Liwu Fu, Sun Yat-Sen University Cancer Center, Guangzhou, 
510060, Guangdong Province, China.  Telephone: +86-20-873-431-63; Fax: +86-20-873-
431-70; E-mail address: Fulw@mail.sysu.edu.cn 
Keywords: 14-3-3σ, DNA repair, PARP1, Chk2, radiation resistance 
Conflict of Interest: The authors declare no conflict of interest. 
Financial Support: This work was supported in part by a grant from NIH (R01 CA140582 
to JTZ). Yifan Chen was supported in part by Sun Yet-sen University. 
_________________________________________________________________________________
 
This is the author's manuscript of the article published in final edited form as: 
Chen, Y., Li, Z., Dong, Z., Beebe, J., Yang, K., Fu, L., & Zhang, J. T. (2017). 14-3-3sigma Contributes to 
Radioresistance by Regulating DNA Repair and Cell Cycle via PARP1 and CHK2. Molecular Cancer Research, 
molcanres-0366.  http://dx.doi.org/10.1158/1541-7786.MCR-16-0366
2 
 
ABSTRACT 
14-3-3σ has been implicated in the development of chemo and radiation resistance 
and in poor prognosis of multiple human cancers. While it has been postulated that 14-3-3σ 
contributes to these resistances via inhibiting apoptosis and arresting cells in G2/M phase of 
the cell cycle, the molecular basis of this regulation is currently unknown. In this study, we 
tested the hypothesis that 14-3-3σ causes resistance to DNA-damaging treatments by 
enhancing DNA repair in cells arrested in G2/M phase following DNA-damaging treatments. 
We showed that 14-3-3σ contributed to ionizing radiation (IR) resistance by arresting cancer 
cells in G2/M phase following IR and by increasing non-homologous end joining (NHEJ) 
repair of the IR-induced DNA double strand breaks (DSBs). The increased NHEJ repair 
activity was due to 14-3-3σ-mediated up-regulation of Poly(ADP-ribose) polymerase 1 
(PARP1) expression that promoted the recruitment of DNA-PKcs to the DNA damage sites 
for repair of DSBs. On the other hand, the increased G2/M arrest following IR was due to 14-
3-3σ-induced Chk2 expression.  
Implications: These findings reveal an important molecular basis of 14-3-3σ function in 
cancer cell resistance to chemo/radiation therapy and in poor prognosis of human cancers. 
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INTRODUCTION 
14-3-3σ is a family member of 14-3-3 proteins (14-3-3β, ε, θ/τ, ζ, σ, γ and η) in 
human and has been implicated in the development of cancer and in treatment resistance and 
poor prognosis (1). While 14-3-3σ is thought to function as a tumor suppressor in mammary 
tissue, its expression has been found to up-regulate in drug resistant cancers of pancreas and 
breast and associates with poor prognosis (2-6). 14-3-3σ has also been found recently to 
regulate invasion of breast cancer cells (7) and EMT (8), which may contribute to poor cancer 
prognosis. 
At the molecular level, 14-3-3σ was though to protect cancer cells against genotoxic 
treatments by regulating cell cycle progression and survival pathways (9,10). Somatic 14-3-
3σ knockout led to mitotic catastrophe upon DNA damages (9). Following DNA damage, 14-
3-3σ-sufficient cells are able to arrest in G2/M phase and survive while 14-3-3σ-deficient 
cells continue to progress through cell cycles and to cell death (11). It, thus, has been 
postulated that 14-3-3σ contributes to survival and DNA-damage resistance by arresting cells 
in G2/M phase (12). However, the molecular mechanism of 14-3-3σ action in this process 
remains unknown. 
Radiation therapy is an important component of cancer treatments. IR impairs the 
survival of cancer cells mainly by causing double strand breaks (DSBs) in the DNA backbone. 
However, increased repair of DSBs would lead to IR resistance. Although DSBs are repaired 
by both homologous recombination (HR) and non-homologous end-joining (NHEJ) 
mechanisms, the latter directly ligates two DSB ends without the need of the template and, 
thus it functions throughout all phases of the cell cycle and is the predominant DSB repair 
pathway in mammalian cells while HR occurs mainly in mid-late S phases (13,14).  
In this study, we tested the hypothesis that 14-3-3σ contributes to radiation resistance 
by up-regulating NHEJ repair while arresting cells in G2/M phase. We found that 14-3-3σ 
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ectopic overexpression increased while its knockdown reduced IR resistance and NHEJ 
repair activity. We also showed that 14-3-3σ-induced increases in NHEJ repair activity was 
via up-regulating Chk2 and by increasing PARP1 expression via up-regulating its 
transcription and inhibiting caspase-mediated degradation of PARP1 protein. Furthermore, 
14-3-3σ up-regulation of PARP1 increased DNA-PKcs recruitment to chromatin DNA, 
facilitating NHEJ repair of DSBs. These findings revealed an important molecular 
mechanism how 14-3-3σ contributes to chemo and radiation resistance and to poor prognosis 
of human cancers. 
MATERIALS AND METHODS 
Materials. Antibodies against 14-3-3σ, Chk1, Chk2 and DNA-PKcs were from EMD 
Millipore (Billerica, MA). The γ-H2AX antibody was from Enzo Biochem (New York, NY). 
14-3-3σ siRNA pool and antibodies against Ku70 and Ku80 were from Santa Cruz 
Biotechnology (Dallas, TX). PARP1 and histone H3 antibodies were from Cell Signaling 
Technology (Danvers, MA). Adriamycin, mitoxantrone, and antibodies against GAPDH, β-
Actin and α-Tubulin were from Sigma-Aldrich (St. Louis, MO). G418, pcDNA3.1(+) 
plasmid, and SYBR Green polymerase chain reaction (PCR) master mix were from Applied 
Biosystems (Grand Island, NY). The iScript cDNA synthesis kit, metafectene Pro 
transfection reagent, and gemcitabine were from Bio-Rad (Hercules, CA), Biontex (München, 
Germany), and Besse Medical (West Chester, OH), respectively. All other chemicals were 
purchased from Sigma-Aldrich or Fisher Scientific (Waltham, MA).  
Cell lines and transfections. BxPC-3 cells with stable 14-3-3σ knockdown or 
harboring scrambled shRNA control were generated in a previous study (2) and cultured in 
RPMI1640 supplemented with 10% fetal bovine serum. MiaPaCa-2 cells with stable over-
expression of ectopic 14-3-3σ and the control cells harboring vector control were also 
generated in a previous study (2) and cultured in (DMEM) supplemented with 10% fetal 
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bovine serum and 2.5% horse serum. All cultures were at 37°C with 5% CO2.  The cell lines 
were authenticated by analysis of tandem repeat sequences on 09/17/2013. 
For transient knockdown, BxPC-3 cells were plated in 6-well plates at 2.0×105 
cells/well and cultured overnight in complete media. About 60 pmol siRNAs targeting 
PARP1, Chk2, or control scrambled siRNA were diluted in serum-free RPMI1640 media and 
transiently transfected into cells using Metafectene Pro as previously described (15). For 
transient knockdown of 14-3-3σ, pSilencer-σ or scrambled shRNA construct engineered in a 
previous study (11) was transfected into BxPC-3 cells using Metafectene Pro transfection 
reagent as previously described (15). The sequences of siRNAs are shown in Supplemental 
Table S1. 
Cytotoxicity assay. Cytotoxicity was determined using MTT and colony formation 
assays as previously described (2,16). MTT assay was used to determine cytotoxicity of 
anticancer drugs. Briefly, cells were seeded in 96-well plate at 3000 cells/well and cultured 
for 24 hrs followed by treatment with anticancer drugs and cultured continuously for 72 hrs at 
37°C. Then, MTT (5 mg/mL) was added to the culture and incubated for another 4 hrs.  The 
culture medium was then aspirated followed by addition of DMSO and absorption was 
determined using a 96-well plate reader. For colony formation assay, 100-200 cells/well were 
seeded in 6-well plate and cultured for 24 hrs before IR treatment. The cells were then 
cultured for 10 days before fixation and staining with crystal violent (0.005% in 20% 
methanol). The colonies were counted manually. Both the fitted sigmoidal dose response 
curve and IC50 were calculated using Graph Pad Prism Program. 
Neutral comet assay. Neutral comet assay was performed using a kit from Trevigen 
(Gaithersburg, MD) according to the manufacturer’s instructions. Briefly, cells were 
harvested at different times following IR and single cell suspensions in PBS at 1×105 cells/ml 
were mixed with low temperature-melting agarose at 37°C and layered onto comet slides. 
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The agarose on slides was allowed to solidify for 1 hour at 4°C, incubated in a pre-chilled 
lysis solution for 30 min at 4°C in the dark, and subjected to electrophoresis. The slides were 
then immersed twice in distilled water for 10 min, once in 70% ethanol for 5 min, dried 
completely at room temperature and stained with SYBR Green I (Trevigen). Comets were 
viewed and recorded using a Zeiss Axiovert 25 fluorescent microscope equipped with a 
camera and analyzed with CometScore V1.5 (TriTek, Sumerduck, VA). The Olive Tail 
Moment was determined by scoring at least 100 cells in each sample(17). 
Cell lysate preparation, Western blot, and immunoprecipitation. Cell lysate 
preparation, Western blot analyses, and immunoprecipitation were performed as previously 
described (4,18). Briefly, cultured cells were harvested, washed with chilled PBS 3 times, and 
lysed in TNN lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40, 
50mM NaF, 1 mM Na3VO4, 1 mM DTT, 0.1% SDS, and 2 mM PMSF) for 30 minutes on ice 
with agitation. The cell lysates were then sonicated briefly followed by centrifugation 
(16,000g at 4°C) for 15 minutes and the supernatant was collected with protein 
concentrations determined using Bradford assay. The cell lysates were then subjected to 
immunoprecipitation and Western blot analyses. 
Immunofluorescence. Immunofluorescence imaging was performed as previously 
described (19). Briefly, 3×105 cells/well were cultured on coverslips in 24-well plate 
overnight followed by IR treatment. At different times after IR, cells were washed with 
chilled PBS, fixed with 50:50 (V:V) acetone/methanol for 10 min, blocked with 1% bovine 
serum albumin in PBS for 30 min, and incubated with anti-γ-H2AX antibody for 1 hr 
followed by washing and incubation with FITC-conjugated goat anti-mouse IgG for 30 min 
all at room temperature. The coverslips were counter-stained with DAPI before mounting on 
slides and viewing with an Olympus 2 confocal microscope. 
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Host cell reactivation-based NHEJ and HR assays. The host cell reactivation-based 
NHEJ assay was performed as previously described with modifications (20). Briefly, 5×104 
cells/well were seeded in 24-well plates and cultured for 24 hrs before transfection with either 
linearized or intact pGL3-Luc plasmid with firefly luciferase reporter gene (400 ng/well) 
using Metafectene Pro. A pRL-TK (Promega) plasmid with renilla luciferase reporter gene 
was co-transfected (20 ng/well) to control transfection efficiency. Linearization of pGL3-Luc 
was achieved by HindIII digestion between CMV promoter and the luciferase gene and 
verified using agarose gel electrophoresis. Cells were harvested at 6 hrs after transfection and 
both the firefly and renilla luciferase activities were determined using a Dual-Luciferase 
Reporter Assay System on a luminometer. Relative NHEJ activity = F. Luclinear×100%/ F. 
Lucintact. 
Host cell reactivation-based HR assay was performed using a kit following 
manufacturer’s instructions (Norgen Biotek Corp).  Briefly, two different deletion mutants 
(dl-1 and dl-2) were engineered form the same parental reporter plasmid and transfected into 
cells individually or in combination. At 24 hrs after transfection, the reporter plasmids were 
recovered from these cells and used as template for real-time PCR analysis of production of 
wild type plasmid from HR reaction.       
Real-time RT-PCR. Firstly, total RNAs were extracted from 1×107 fresh cells using 
the RNeasy Mini Kit (Qiagen) following the manufacturer's protocol. All RNA samples were 
treated with RNase-free DNase I (Promega) and quantified using a Nanodrop 
spectrophotometer (Fisher Scientific). For reverse transcription, 1 µg DNA-free RNA was 
used for cDNA synthesis using iScript cDNA synthesis kit (Bio-Rad) following the 
manufacturer's protocol exactly without any modification. 
Real-time RT-PCR was performed using SYBR Green PCR master mix as previously 
described (Applied Biosystems) (21). Relative mRNA levels were quantified using the 
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comparative Ct method by normalizing to the endogenous reference gene GAPDH and given 
by 2∆∆Ct where ∆Ct=Ct(target gene)-Ct(GAPDH) and ∆∆Ct=∆Ct(test sample)- ∆Ct(control sample). Three 
independent experiments were performed with each in triplicate determinations. 
Supplemental Table S2 shows the primer sequences, which have been used to blast 
nucleotide database and no gene other than the targeted ones were found.  
Subcellular fractionation. Subcellular fractionation was performed as previously 
described (22,23). Briefly, cells were harvested, washed with PBS, and lysed in buffer A (10 
mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM 
DTT and 2 mM PMSF) containing 0.1% Triton X-100 on ice for 10 min followed by 
centrifugation (1,300×g for 5 min at 4°C) to collect crude nuclei fraction (pellet). The 
supernatant was subjected to high-speed centrifugation (20,000×g for 5 min at 4°C) to collect 
the supernatant (cytosolic fraction). The low-speed pellet was subjected to lysis in buffer B (3 
mM EDTA, 0.2 mM EGTA, 1 mM DTT and 2 mM PMSF) on ice for 30 min followed by 
centrifugation (1,700×g for 5 min at 4°C) to separate soluble nuclear (supernatant) and 
chromatin-bound (pellet) fractions.  
Pulse labeling. Pulse labeling was performed as previously described (24). Briefly, 
6×105 cells were seeded in 10-cm dish and cultured for 72 hrs. The cells were washed twice 
with PBS and once with RPMI1640 lacking methionine followed by incubation for 2 hrs in 
the same medium supplemented with 75 μCi/ml [35S]methionine. The labeled cells were then 
washed with PBS and harvested for lysate preparation and immunoprecipitation as described 
above. The immunoprecipitated proteins were separated by SDS-PAGE and signals of newly 
synthesized proteins were captured using X-ray films. 
Cell cycle analysis. Cell cycle analysis was performed as previously described (25). 
Briefly, 2×105 cells were seeded in 6-well plates followed by IR treatment. Cells were 
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collected at different times, fixed in cold 75% ethanol and stained with 50 μg/ml PI followed 
by analysis with FACS. 
RESULTS 
14-3-3σ contributes to cellular resistance to DNA-damaging drugs and IR. To 
determine the role of 14-3-3σ in cellular response to DNA-damaging drugs and IR, we took 
advantage of the previously established stable cell lines MiaPaCa-2/σ with over-expression of 
ectopic 14-3-3σ and BxPC-3/Sh-σ with knockdown of endogenous 14-3-3σ (Figure 1A). The 
parental BxPC-3 cells express high levels of endogenous 14-3-3σ, equivalent to that in 
human pancreatic cancer tissues (2) while MiaPaCa-2 cells lack endogenous 14-3-3σ (2), 
which are good models for knockdown and over-expression studies, respectively. Firstly, we 
subjected these cells to MTT survival assay following treatments with gemcitabine, 
mitoxantrone, or doxorubicin. As shown in Figure 1B, MiaPaCa-2/σ cells are significantly 
more resistant than the control vector-transfected MiaPaCa-2/Vec cells. Consistently, the 
stable BxPC-3/Sh-σ cells are significantly more sensitive to these drugs than the control 
BxPC-3/Scr cells. We next tested their response to IR treatments using colony formation 
survival assay. As shown in Figure 1C and supplemental Figure S1, higher expression level 
of 14-3-3σ also significantly increased cellular tolerance of IR.  
We also tested another cell line, H1299 that expresses little endogenous 14-3-3σ (26), 
by stably over-expressing ectopic 14-3-3σ (H1299/σ) (Figure S2A). As shown in Figure S2B, 
H1299/σ was more resistant to IR than the control H1299/Vec cells. These studies suggest 
that 14-3-3σ contributes to cellular resistance to DNA-damaging drugs and IR in different 
human cancer cells.  
14-3-3σ modulates γ-H2AX clearance and DSB accumulation. To determine if 14-3-
3σ-mediated DNA-damage resistance is possibly due to its regulation of DNA repair, we first 
examined the accumulation of IR-induced DNA damages at different times following IR in 
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these cells by examining γ-H2AX, a marker of DNA damages. As shown in Figure 2A, low 
basal level of γ-H2AX was detected similarly in both MiaPaCa-2/σ and the control MiaPaCa-
2/Vec cells without IR treatment. At 1 hr post IR, γ-H2AX level dramatically increased in 
both cells. However, MiaPaCa-2/σ cells have much lower level of γ-H2AX than the control 
MiaPaCa-2/Vec cells, indicating that MiaPaCa-2/Vec cells have accumulated more DNA 
damages than the MiaPaCa-2/σ cells. While the γ-H2AX level continued to decrease with 
time in MiaPaCa-2/σ cells and reached the basal level at 24 hrs post IR, it remained at high 
levels in the MiaPaCa-2/Vec control cells at 24 hrs after IR. Similarly, the basal level of γ-
H2AX was very low in both BxPC-3/Sh-σ and its control BxPC-3/Scr cells and the γ-H2AX 
level dramatically increased in both cells at 1 hr post IR (Figure 2B). However, BxPC-3/Sh-σ 
cells have more γ-H2AX than BxPC-3/Scr cells and it dissipated much slower in BxPC-3/Sh-
σ than in BxPC-3/Scr cells. Consistently, we also found that at 1 hr post IR, both H1299/σ 
and H1299/Vec cells have much higher level of γ-H2AX than the control un-irradiated cells 
(Figure S3). However, at 24 hrs after IR, the γ-H2AX level returned to the basal level in 
H1299/σ cells while it remained high in the control H1299/Vec cells. 
To confirm above findings, we performed immunofluorescence staining of γ-H2AX 
following IR. As shown in Figure 2C-D, little staining was observed in the control untreated 
cells. At 1 hr post IR, punctate nuclear staining of γ-H2AX dramatically increased in all cells. 
However, at 6 hrs post IR the staining of H2AX dissipated in MiaPaCa-2/σ and BxPC-3/Vec 
cells, which express high levels of 14-3-3σ, while the staining remained high in MiaPaCa-
2/Vec and BxPC-3/Sh-σ cells, which express little 14-3-3σ.  
To further determine the role of 14-3-3σ in removing DNA damages, we performed 
neutral comet assay following IR. As shown in Figure 2E-H, similar levels of DNA damages 
were generated by IR in all cells at 1 hr post IR, indicated by Olive tail moment. However, at 
6 hrs after IR MiaPaCa-2/σ cells have significantly less Olive tail moment than the control 
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MiaPaCa-2/Vec cells while BxPC-3/Sh-σ cells have significantly more Olive tail moment 
than the control BxPC-3/Scr cells. Together, these findings suggest that 14-3-3σ may increase 
repair of IR-induced DSBs. 
14-3-3σ promotes NHEJ repair of DSBs. To assess directly if 14-3-3σ increases repair 
of IR-induced DSBs, we first examined the effect of 14-3-3σ on NHEJ activity by performing 
a host-cell-reactivation-based NHEJ assay in these cells. As shown in Figure 3A, cells 
expressing high levels of ectopic (MiaPaCa-2/σ) or endogenous (BxPC-3/Scr) 14-3-3σ had 2-
3 fold higher NHEJ activity than the cells expressing little or no 14-3-3σ (BxPC-3/Sh-σ and 
MiaPaCa-2/Vec). Similarly, NHEJ repair activity was also significantly increased in H1299/σ 
cells compared with the control H1299/Vec cell (Figure S4A). However, 14-3-3σ may not 
affect HR repair as determined using host-cell-reactivation-based HR assay of the BxPC-
3/Sh-σ and BxPC-3/Scr cell pair (Figure S4B). Interestingly, HR repair was significantly 
increased in H1299/σ cells compared with the control H1299/Vec cell (Figure S4C). Thus, 
14-3-3σ positively regulates the NHEJ repair of DSBs and also possibly HR but in a cell line-
dependent manner.  
14-3-3σ promotes recruitment of DNA-PKcs. Because 14-3-3σ regulation of HR 
repair appears to be cell line-dependent, we decided to focus on NHEJ in the following 
studies. To understand the mechanism of 14-3-3σ action in regulating NHEJ, we first tested 
its effect on the expression of genes in the DNA-PK complex, Ku70, Ku80, and DNA-PKcs, 
which plays an important role in NHEJ. As shown in Figure 3B, 14-3-3σ had no discernible 
effect on the total level of Ku70, Ku80 and DNA-PKcs. Next, we determined the effect of 14-
3-3σ on recruitment of the DNA-PK complex onto damaged chromatin following IR. For this 
purpose, we first isolated cytosolic, soluble nuclear and chromatin-bound proteins followed 
by Western blot analysis of Ku70, Ku80, and DNA-PKcs in these fractions. As shown in 
Figure 3C, the cells expressing high levels of 14-3-3σ (MiaPaCa-2/σ and BxPC-3/Scr) 
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enhanced both the basal and IR-induced recruitment of DNA-PKcs to chromatin compared 
with the cells expressing little 14-3-3σ (MiaPaCa-2/Vec and BxPC-3/Sh-σ). However, the 
recruitment of Ku70 and Ku80 was not affected by altering 14-3-3σ expression. Thus, 14-3-
3σ regulates NHEJ repair of DSBs possibly by promoting recruitment of DNA-PKcs to the 
damaged DNAs. 
PARP1 mediates 14-3-3σ regulation of NHEJ. It has been reported that PARP1 
participates in the NHEJ repair pathway (27) by PARylating and recruiting DNA-PK proteins 
(28). To test the possible role of PARP1 in mediating 14-3-3σ regulation of DNA-PKcs 
recruitment, we first determined if 14-3-3σ regulates PARP1 expression by testing the stable 
BxPC-3/Sh-σ and MiaPaCa-2/σ cells in comparison with their respective control cells using 
Western blot and real-time RT-PCR analysis. As shown in Figure 4A-B, BxPC-3/Sh-σ had 
reduced while MiaPaCa-2/σ had increased levels of PARP1 protein and mRNA compared 
with their respective control cells. Transient 14-3-3σ knockdown in BxPC-3 cells using two 
different shRNAs or a siRNA pool as describe previously (4) also successfully reduced 
PARP1 expression (Figure 4C).  
The altered transcription of PARP1 by 14-3-3σ likely resulted in altered synthesis of 
PARP1 and change in PARP1 protein level. To test this possibility, we performed a pulse-
labeling experiment in combination with immunoprecipitation of PARP1 followed by 
separation on SDS-PAGE and autoradiography. As shown in Figure 4D, indeed PARP1 
protein synthesis was dramatically decreased in BxPC-3/Sh-σ cells and dramatically 
increased in MiaPaCa-2/σ cells compared with their respective control cells. Thus, 14-3-3σ 
regulates PARP1 expression, which in turn contributes to NHEJ repair of DSBs. However, it 
is noteworthy that the effect of 14-3-3σ on PARP1 appears to be more dramatic as 
determined using pulse labeling (Figure 4D) than Western blot (Figure 4A). While Western 
blot determines the steady state level of the protein, the pulse labeling shows the transient 
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level of proteins that are labeled by [35S]methionine, which may amplify the difference 
between the control and 14-3-3σ-altered cells. 
Next, we determined the effect of PARP1 knockdown on NHEJ. As shown in Figure 
5A, PARP1 knockdown in BxPC-3 cells using two different siRNAs had not effect on the 
expression of DNA-PKcs or 14-3-3σ. However, the knockdown significantly reduced NHEJ 
activity (Figure 5B) and recruitment of DNA-PKcs to chromatin (Figure 5C). Consistently, 
PARP1 knockdown in MiaPaCa-2/σ cells with overexpression of ectopic 14-3-3σ using the 
same siRNA had not effect on the expression of DNA-PKcs or 14-3-3σ (Figure S5A), but 
reduced DNA-PKcs recruitment in these cells (Figure S5B). Thus, it is possible that PARP1 
mediates 14-3-3σ regulation of DNA-PKcs recruitment. 
14-3-3σ inhibits IR-induced apoptosis. The above studies showed that 14-3-3σ might 
up-regulate NHEJ repair of IR-induced DSB by increasing PARP1 expression and DNA-
PKcs recruitment. The increased DNA repair likely contributes to the increased cellular 
survival and resistance to IR. To test this possibility, we determined the effect of 14-3-3σ on 
IR-induced apoptosis. As shown in Figure 6A, activation and cleavage of caspase 9 and 
executioner caspase 3 induced by IR is dramatically inhibited in MiaPaCa-2/σ cells compared 
with the control MiaPaCa-2/Vec cells. Consistently, their activation and cleavage following 
IR are increased in BxPC-3/Sh-σ cells compared with the control BxPC-3/Scr cells. We also 
found that PARP1 cleavage by caspases, an indicator of apoptosis, was inhibited in MiaPaCa-
2/σ and increased in BxPC-3/Sh-σ cells following IR. Thus, we conclude that 14-3-3σ 
protects cancer cells against IR-induced apoptosis by increasing the repair of IR-induced 
DNA damages. 
14-3-3σ regulation of Chk2 expression in G2/M arrest for NHEJ repair. Previously, it 
has been suggested that 14-3-3σ plays an important role in regulating cell cycle and help 
arrest cells in G2/M phase following DNA damage to allow efficient repair of the DNA 
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damages and to prevent mitotic catastrophe and apoptosis (29,30). Others and we have also 
shown that 14-3-3σ helps arrest cells in G2/M phase following DNA-damages (9,11,25). To 
determine how 14-3-3σ regulates cell cycle progression, we first analyzed cell cycle 
distribution of MiaPaCa-2/σ and BxPC-3/Sh-σ cells in comparison with their respective 
control cells following IR. As shown in Figure 7A-B, the untreated BxPC-3/Scr and 
MiaPaCa-2/σ cells with high level of 14-3-3σ had slightly more enrichment of G2/M 
population than MiaPaCa-2/Vec and BxPC-3/ Sh-σ cells with little 14-3-3σ, respectively. 
However, 14-3-3σ knockdown in BxPC-3 cells (BxPC-3/Sh-σ) caused remarkably less 
accumulation in G2/M population at 24 hrs post IR compared with the control BxPC-3/Scr 
cells (Figure 7A). For MiaPaCa-2/σ cells compared with the control MiaPaCa-2/Vec cells, 
the difference in G2/M population can be clearly observed at 6 and 12 hrs post IR treatment 
(Figure 7B).  
To investigate how 14-3-3σ regulates G2/M arrest in response to IR, we determined 
the potential effect of 14-3-3σ on the expression of Chk2, which regulates several 
downstream effector molecules that are known ligand substrates of 14-3-3 proteins (12) and 
important for cell cycle progression following DNA damage (31). As shown in Figure 7C, 
Chk2 expression is up-regulated in MiaPaCa-2/σ and down-regulated in BxPC-3/Sh-σ cells 
compared with their respective control MiaPaCa-2/Vec and BxPC-3/Scr cells as determined 
using Western blot. Real-time RT-PCR analysis showed that the Chk2 mRNA is also 
increased in MiaPaCa-2/σ cells and decreased in BxPC-3/Sh-σ cells (Figure 7D). Similar 
findings were also observed with H1299/σ and H1299/Vec cell pair (Figure S6). Thus, 14-3-
3σ likely up-regulates Chk2 expression in addition to up-regulating PARP1 expression. 
To determine if Chk2 potentially mediates 14-3-3σ function in G2/M arrest following 
DNA damage, we first knocked known Chk2 expression in MiaPaCa-2/σ and MiaPaCa-
2/Vec cells using three different siRNAs followed by treatment with IR before determining 
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cell cycle distribution. As shown in Figure 7E-F, siRNA1 had no effect on Chk2 expression 
while siRNA#2 and siRNA#3 significantly knocked down Chk2 expression with different 
efficiency with siRNA#2 most effective, which was chosen for further study. As shown in 
Figure 7G, the scrambled siRNA-transfected MiaPaCa-2/σ cells have more G2/M population 
than MiaPaCa-2/Vec cells with or without IR treatment, consistent with the data shown in 
Figure 7B. However, Chk2 knockdown in MiaPaCa-2/σ cells eliminated the 14-3-3σ-induced 
increase in G2/M population. Thus, Chk2 may mediate 14-3-3σ-induced G2/M arrest 
following DNA damages. 
To determine if 14-3-3σ-induced G2/M arrest enhances NHEJ repair of IR-induced 
DSB, we tested the effect of eliminating G2/M arrest by Chk2 knockdown on 14-3-3σ-
induced NHEJ activity using the HCR assay as described above. As shown in Figure 7H, 
Chk2 knockdown in MiaPaCa-2/σ cells by siRNA#2 eliminated 14-3-3σ-induced NHEJ 
activity. It is also noteworthy that the siRNA#3 only slightly attenuated the 14-3-3σ-induced 
NHEJ activity, consistent with its lower activity in knocking down Chk2 expression (Figure 
7E-F). Thus, we conclude that 14-3-3σ up-regulates Chk2 expression to arrest cells at G2/M 
phase following DNA damage, which may contribute to 14-3-3σ-induced NHEJ repair of IR-
induced DSBs. 
14-3-3σ regulation of Chk2 may be via PARP1. The above studies show that 14-3-3σ 
regulates both Chk2 and PARP1 expression. To determine if these regulations are 
independent events or have a linear relationship, we tested Chk2 and PARP1 expressions 
following their knockdowns. As shown in Figure S7A, PARP1 knockdown in BxPC-3 cells 
led to reduced Chk2 expression. However, Chk2 knockdown had no effect on PARP1 
expression (Figure S7B). Thus, 14-3-3σ regulation of Chk2 expression may be via regulating 
PARP1. 
DISCUSSION 
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Efficient DNA repair is considered as one of the major mechanisms that contribute to 
chemo and radiation resistance. While 14-3-3σ has been suggested to contribute to these 
resistances by arresting cells in G2/M phase for repair of DNA damages, this hypothesis has 
not been tested previously. Here, we showed that 14-3-3σ contributed IR resistance possibly 
by regulating cell cycle progression and NHEJ repair of IR-induced DSBs via regulating the 
expression of Chk2 and PARP1. These findings not only illustrate the molecular mechanisms 
of 14-3-3σ action in chemo and radiation resistance but also suggest that 14-3-3σ may be an 
upstream master regulator in chemo and radiation resistance and cancer cell survival. It is 
also noteworthy that 14-3-3σ has been shown to contribute to cisplatin resistance (1). 
Although the detailed mechanism for cisplatin resistance is unknown, it is tempting to 
speculate that 14-3-3σ may contribute to nucleotide excision repair of cisplatin-DNA adducts 
via NHEJ repair of DSB produced from these adducts. 
The involvement of PARP1 in NHEJ repair (27) may be via PARylating and by 
increasing DNA-PKcs recruitment (28,32-34). Our finding that 14-3-3σ increase DNA-PKcs 
recruitment possibly via increasing PARP1 is consistent with these previous observations. 
Interestingly, 14-3-3σ has no effect on the expression or recruitment of Ku proteins. It 
remains unknown if Ku proteins are abundantly bound to chromatin and if DNA-PKcs may 
serve as a limiting factor for NHEJ repair of DSBs in BxPC-3 and MiaPaCa-2 cells. However, 
it has been reported previously that increased Ku70 expression promotes cellular resistance to 
IR in human cancer cells (35-37).  
Previously, it has been suggested that 14-3-3σ binds to cdk2 and cdc25A, the 
downstream effectors of Chk2, and arrests them in cytoplasm, which results in G2/M arrest 
following DNA damages (38-40). Together with our finding that 14-3-3σ up-regulates Chk2 
expression, we conclude that 14-3-3σ may act at multiple points in regulating cell cycle 
progression in response to DNA damages.  
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Although we have shown here that 14-3-3σ contributes to IR resistance by arresting 
cancer cells in G2/M phase and by increasing NHEJ repair via up-regulating Chk2 and 
PARP1 expression, it remains to be determined how 14-3-3σ regulates the expression of 
these genes. The finding that the mRNA levels of Chk2 and PARP1 were altered by 14-3-3σ 
suggests that 14-3-3σ may regulate the transcription of these genes. Although it has been 
shown that Chk2 expression is negatively regulated by p53 (41,42) and 14-3-3σ regulates p53 
(43), p53 in BxPC-3 cells is inactive due to mutation and, thus, may not mediate 14-3-3σ 
regulation of Chk2 expression in these cells. However, PARP1 may mediate 14-3-3σ 
regulation of Chk2 expression. Recently, we have shown that the PARP1 gene promoter 
contains a NF-κB-binding element and that NF-κB negatively regulates PARP1 expression in 
another cell line, Panc-1 (20). It has also been shown that 14-3-3 proteins could bind to both 
p65 and IκBα and facilitate the nuclear export of IκBα-p65 complexes (44). Therefore, it is 
tempting to speculate that 14-3-3σ may bind to and arrest p65 in the cytoplasm and, thus, 
blocks p65 negative regulation of PARP1 promoter activity, resulting in increased PARP1 
expression, which in turn regulates Chk2 expression.  
It is of interest to note that PARP1 is also a substrate of apoptosis executioner 
caspases while participating in NHEJ repair of DSBs. In this study, we showed that 14-3-3σ 
up-regulates PARP1 transcription and prevents PARP1 cleavage due to apoptosis. The role of 
14-3-3σ in resisting apoptosis has previously been shown and possibly via binding to and 
arresting pro-apoptotic proteins (10,45). The inhibition in PARP1 cleavage due to inhibition 
of apoptosis and the increased PARP1 expression by 14-3-3σ may form a feed-forward loop 
of DNA repairs for cancer cell survival against DNA-damaging drug and radiation treatments.  
Although both NHEJ and HR mechanisms are responsible for repair of DSBs, it 
appears that the 14-3-3σ regulation of DSB repair via HR is cell-line-dependent. While it 
regulates HR in H1299 cells, it does not appear to do so in BxPC-3 cells, which are known to 
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have wild type BRCA1 and BRCA2 (46). The cause of this cell line specificity in HR 
regulation is unknown. However, this finding is not surprising if 14-3-3σ regulation of DSB 
repair is via PARP-1 since the role of PARP-1 in regulating HR repair varies in different 
studies and PARP-1 may also controls the choice of the pathways for DSB repair (47). While 
PARP1 has been shown to activate HR repair (48),  PARP-1 may also inhibit HR by 
preventing the HR machinery from recognizing and processing DNA lesions possibly by 
PARylating BRCA1 and inhibiting its activity, or by inhibiting the expression of BRCA1 and 
BRCA2 (49-54).  Because NHEJ is associated with faster rate of repair compared to HR 
(55,56), consistent 14-3-3σ up-regulation of NHEJ repair in different cancer cells likely 
provides an efficient survival mechanism against DNA-damaging treatments to cancer cells.  
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FIGURE LEGENDS 
Figure 1. 14-3-3σ contributes to cellular resistance to DNA-damaging drugs and 
IR. (A) Western blot analysis of 14-3-3σ in stable MiaPaCa-2/Vec and MiaPaCa-2/σ and in 
BxPC-3/Scr and BxPC-3/Sh-σ cells. (B) MTT assay of survival against different therapeutic 
drugs. GEM, gemcitabine; MTX, mitoxantrone; DOX, doxorubicin. Relative resistance factor 
(REF)=IC50(MiaPaCa-2/σ)/IC50(MiaPaCa-2/Vec) or IC50(BxPC-3/Sh-σ)/IC50(BxPC-3/Scr). (C) Colony formation 
assay of survival against IR. (*p<0.05; **p<0.01; n=3). 
Figure 2. 14-3-3σ modulates IR-induced γ-H2AX and DSB accumulation. (A-D) 
Western blot (A-B) and immuno-fluorescence staining (C-D) of γ-H2AX following IR 
treatment in in stable MiaPaCa-2/Vec and MiaPaCa-2/σ and in BxPC-3/Scr and BxPC-3/Sh-σ 
cells. (E-H) Comet assay of DSB accumulation in in stable MiaPaCa-2/Vec and MiaPaCa-2/σ 
(E, G) and in BxPC-3/Scr and BxPC-3/Sh-σ (F, H) cells. Olive Tail Moment=(tail mean–head 
mean)×(% of DNA in the tail) from 100 cells in each sample of 3 independent experiments 
scored by CometScore 1.5. (*p < 0.05; **p< 0.01).  
Figure 3. 14-3-3σ promotes NHEJ repair of DSBs via DNA-PKcs. (A) Host cell 
reactivation assay of NHEJ activity. (**p<0.01; n=3). (B-C) Western blot analysis of Ku70, 
Ku80, DNA-PKcs expression (B) and recruitment to damaged chromatin DNA (C) following 
IR treatments. Tubulin and histone were used as cytosolic and nuclear fraction marker, 
respectively.  
Figure 4. 14-3-3σ regulation of PARP1 expression. (A-C) Western blot (A and C) 
and real time RT-PCR (B) analyses of PARP1 expression in MiaPaCa-2 and BxPC-3 cells 
with altered 14-3-3σ expression. (**p<0.01; n=3). (D) PARP1 protein synthesis as 
determined using pulse-labeling with [35S]methionine, immunoprecipitation, and SDS-PAGE 
analysis. 
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Figure 5. Role of PARP1 in DNA-PKcs recruitment and NHEJ activity. (A) 
Western blot analysis of PARP1 effect on DNA-PKcs expression. (B) Host cell reactivation 
assay of PARP1 effect on NHEJ activity. (*p< 0.05; **p< 0.01; n=3). (C) Western blot 
analysis of PARP1 effect on DNA-PKcs recruitment. 
Figure 6. 14-3-3σ inhibits IR-induced apoptosis. Western blot analysis of caspase 
activation/cleavage (cCasp) and PARP1 cleavage (cPARP1) in MiaPaCa-2/Vec and 
MiaPaCa-2/σ cells prior to or after IR treatments.  
Figure 7. 14-3-3σ regulation of G2/M arrest and Chk2 expression.  (A-B) Cell 
cycle distribution of MiaPaCa-2/σ and BxPC-3/Sh-σ in comparison with their respective 
control cells following IR. (C-D) Western blot (C) and real time RT-PCR (D) analysis of 
Chk2 expression in MiaPaCa-2/σ and BxPC-3/Sh-σ in comparison with their respective 
control cells. (E-F) Western blot (E) and real-time RT-PCR (F) analyses of Chk2 knockdown 
by siRNAs. (G) FACS analysis of Chk2 knockdown on cell cycle distribution following IR in 
MiaPaCa-2/σ cells. (H) Host cell reactivation assay of the effect of Chk2 knockdown on 14-
3-3σ-induced NHEJ activity increase. (*p<0.05; **p<0.01; n=3).  
 







